sellWeak cluster of 210b5-1 plan
BENKOWITZ MICHAEL sold $3.7M of UTHR
PRESIDENT AND COO at UNITED THERAPEUTICS Corp. 10,000 shares at an average of $367.69, traded Dec 9, 2024, filed Dec 10, 2024.
Warning score
38Value
$3.7M
10,000 shares
Holdings after
0
-137% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001562180-24-008301, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 9, 2024 | MOption exercise Common Stockindirect: By Trust10b5-1 | +4,500 | $102.11 | $459k | 4,500 | Dec 10, 2024 |
| Dec 9, 2024 | MOption exercise Common Stockindirect: By Trust10b5-1 | +3,000 | $111.00 | $333k | 3,000 | Dec 10, 2024 |
| Dec 9, 2024 | SOpen-market sale Common Stockindirect: By Trust10b5-1 | -926 | $366.27 | $339k | 6,359 | Dec 10, 2024 |
| Dec 9, 2024 | SOpen-market sale Common Stockindirect: By Trust10b5-1 | -215 | $364.92 | $78k | 7,285 | Dec 10, 2024 |
| Dec 9, 2024 | SOpen-market sale Common Stockindirect: By Trust10b5-1 | -3,481 | $367.54 | $1.3M | 2,878 | Dec 10, 2024 |
| Dec 9, 2024 | SOpen-market sale Common Stockindirect: By Trust10b5-1 | -2,700 | $368.28 | $994k | 178 | Dec 10, 2024 |
| Dec 9, 2024 | SOpen-market sale Common Stockindirect: By Trust10b5-1 | -100 | $370.75 | $37k | 78 | Dec 10, 2024 |
| Dec 9, 2024 | SOpen-market sale Common Stockindirect: By Trust10b5-1 | -78 | $372.39 | $29k | 0 | Dec 10, 2024 |
| Dec 9, 2024 | MOption exercise Common Stockindirect: By Trust10b5-1 | +2,500 | $111.00 | $278k | 2,500 | Dec 10, 2024 |
| Dec 9, 2024 | SOpen-market sale Common Stockindirect: By Trust10b5-1 | -100 | $364.87 | $36k | 2,400 | Dec 10, 2024 |
| Dec 9, 2024 | SOpen-market sale Common Stockindirect: By Trust10b5-1 | -393 | $366.58 | $144k | 2,007 | Dec 10, 2024 |
| Dec 9, 2024 | SOpen-market sale Common Stockindirect: By Trust10b5-1 | -1,300 | $367.73 | $478k | 707 | Dec 10, 2024 |
| Dec 9, 2024 | SOpen-market sale Common Stockindirect: By Trust10b5-1 | -607 | $368.47 | $224k | 100 | Dec 10, 2024 |
| Dec 9, 2024 | SOpen-market sale Common Stockindirect: By Trust10b5-1 | -100 | $370.75 | $37k | 0 | Dec 10, 2024 |
| Dec 9, 2024 | MOption exercise Stock Optionsderivativeindirect: By Trust10b5-1 | -4,500 | $0.00 | $0 | 0 | Dec 10, 2024 |
| Dec 9, 2024 | MOption exercise Stock Optionsderivativeindirect: By Trust10b5-1 | -3,000 | $0.00 | $0 | 4,148 | Dec 10, 2024 |
| Dec 9, 2024 | MOption exercise Stock Optionsderivativeindirect: By Trust10b5-1 | -2,500 | $0.00 | $0 | 32,000 | Dec 10, 2024 |
Related signals
Other insiders at UNITED THERAPEUTICS Corp and this insider’s other filings.
| Score | Side | Company | Insider | Value | Shares | Filed |
|---|---|---|---|---|---|---|
| 38Weak | sell 210b5-1 | UTHR UNITED THERAPEUTICS Corp | BENKOWITZ MICHAEL PRESIDENT AND COO | $3.6M | 10,000 | |
| 32Weak | sell 2 | UTHR UNITED THERAPEUTICS Corp | Mesa Nilda director | $91k | 255 | |
| 38Weak | sell 210b5-1 | UTHR UNITED THERAPEUTICS Corp | BENKOWITZ MICHAEL PRESIDENT AND COO | $3.6M | 10,000 | |
| 45Moderate | sell 310b5-1 | UTHR UNITED THERAPEUTICS Corp | BENKOWITZ MICHAEL PRESIDENT AND COO | $3.7M | 10,000 | |
| 18Weak | sell 210b5-1 | UTHR UNITED THERAPEUTICS Corp | MAHON PAUL A EVP & GENERAL COUNSEL | $2.9M | 7,700 | |
| 38Weak | sell 210b5-1 | UTHR UNITED THERAPEUTICS Corp | BENKOWITZ MICHAEL PRESIDENT AND COO | $3.7M | 10,000 | |
| 45Moderate | sell 310b5-1 | UTHR UNITED THERAPEUTICS Corp | BENKOWITZ MICHAEL PRESIDENT AND COO | $3.7M | 10,000 | |
| 25Weak | sell 410b5-1 | UTHR UNITED THERAPEUTICS Corp | MAHON PAUL A EVP & GENERAL COUNSEL | $2.8M | 7,700 | |
| 45Moderate | sell 610b5-1 | UTHR UNITED THERAPEUTICS Corp | BENKOWITZ MICHAEL PRESIDENT AND COO | $3.6M | 10,000 | |
| 45Moderate | sell 710b5-1 | UTHR UNITED THERAPEUTICS Corp | BENKOWITZ MICHAEL PRESIDENT AND COO | $6.1M | 15,000 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.